Fundsmith Llp buys $490,853,512 stake in IDEXX Laboratories (IDXX)

IDEXX Laboratories (IDXX) : Fundsmith Llp scooped up 21,547 additional shares in IDEXX Laboratories during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Nov 14, 2016. The investment management firm now holds a total of 4,490,883 shares of IDEXX Laboratories which is valued at $490,853,512.IDEXX Laboratories makes up approximately 7.12% of Fundsmith Llp’s portfolio.

Other Hedge Funds, Including , Oppenheimerfunds boosted its stake in IDXX in the latest quarter, The investment management firm added 138,640 additional shares and now holds a total of 141,426 shares of IDEXX Laboratories which is valued at $15,457,862. IDEXX Laboratories makes up approx 0.02% of Oppenheimerfunds’s portfolio.Proshare Advisors reduced its stake in IDXX by selling 2,103 shares or 20.26% in the most recent quarter. The Hedge Fund company now holds 8,276 shares of IDXX which is valued at $900,098. IDEXX Laboratories makes up approx 0.01% of Proshare Advisors’s portfolio.Acrospire Investment Management boosted its stake in IDXX in the latest quarter, The investment management firm added 1,600 additional shares and now holds a total of 2,300 shares of IDEXX Laboratories which is valued at $250,148. IDEXX Laboratories makes up approx 0.17% of Acrospire Investment Management’s portfolio.Boston Family Office reduced its stake in IDXX by selling 327 shares or 1.68% in the most recent quarter. The Hedge Fund company now holds 19,166 shares of IDXX which is valued at $2,013,772. IDEXX Laboratories makes up approx 0.28% of Boston Family Office’s portfolio.

IDEXX Laboratories opened for trading at $115.53 and hit $116.5 on the upside on Monday, eventually ending the session at $116.13, with a gain of 0.82% or 0.94 points. The heightened volatility saw the trading volume jump to 4,90,275 shares. Company has a market cap of $10,412 M.

On the company’s financial health, IDEXX Laboratories reported $0.62 EPS for the quarter, beating the analyst consensus estimate by $ 0.02 according to the earnings call on Nov 1, 2016. Analyst had a consensus of $0.60. The company had revenue of $448.31 million for the quarter, compared to analysts expectations of $449.10 million. The company’s revenue was up 10.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.48 EPS.

Many Wall Street Analysts have commented on IDEXX Laboratories. IDEXX Laboratories was Resumed by BofA/Merrill to “Neutral” on Sep 29, 2016.

IDEXX Laboratories Inc. develops manufactures and distributes products and provides services primarily for the companion animal veterinary livestock and poultry water testing and dairy markets. The Company sells a line of portable electrolytes and blood gas analyzers for the human point-of-care medical diagnostics market. Its segments include Companion Animal Group (CAG) Water Livestock Poultry and Dairy and Other. Its Products and services include point-of-care veterinary diagnostic products; veterinary reference laboratory diagnostic and consulting services; practice management systems and services and digital imaging systems; biological materials testing laboratory animal diagnostic instruments and services; diagnostic health-monitoring and food safety testing products for livestock poultry and dairy; products that test water for microbiological contaminants and point-of-care electrolytes and blood gas analyzers for the human point-of-care medical diagnostics market.

Leave a Reply

IDEXX Laboratories - Is it time to Sell?

Top Brokerage Firms are advising their investors on IDEXX Laboratories. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.